Cost-effectiveness analysis of cetuximab in treatment of metastatic colorectal cancer in Iranian pharmaceutical market
نویسندگان
چکیده
منابع مشابه
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
Health technology The study examined the combination of cetuximab and irinotecan as third-line treatment for metastatic colorectal cancer (mCRC). This chemotherapy strategy was compared with current standard treatment, which usually consists of follow-up (no third-line chemotherapy). An initial dose of 400 mg/m2 cetuximab intravenously was followed by 250 mg/m2 weekly until disease progression ...
متن کاملCost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
PURPOSE We conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (FIRE-3) data to evaluate clinical and economic tradeoffs associated with first-line treatments of KRAS wild-type (WT) metastatic colorectal cancer (mCRC). MATERIALS AND METHODS A cost-effectiveness model was developed using FIRE-3 data to project survival and lifetime costs of FOLFIRI plus either...
متن کاملanalysis of power in the network society
اندیشمندان و صاحب نظران علوم اجتماعی بر این باورند که مرحله تازه ای در تاریخ جوامع بشری اغاز شده است. ویژگیهای این جامعه نو را می توان پدیده هایی از جمله اقتصاد اطلاعاتی جهانی ، هندسه متغیر شبکه ای، فرهنگ مجاز واقعی ، توسعه حیرت انگیز فناوری های دیجیتال، خدمات پیوسته و نیز فشردگی زمان و مکان برشمرد. از سوی دیگر قدرت به عنوان موضوع اصلی علم سیاست جایگاه مهمی در روابط انسانی دارد، قدرت و بازتولید...
15 صفحه اولRAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
PURPOSE To test the cost-effectiveness of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment in patients with metastatic colorectal cancer (mCRC) from a Chinese medical insurance perspective. RESULTS Baseline analysis showed that the addition of cetuximab increased quality-adjusted life-years (QALYs) by 0.63, an increase of $17,086 relative to FOLFIRI ch...
متن کاملCetuximab: in the treatment of metastatic colorectal cancer.
Cetuximab is a chimeric monoclonal antibody highly selective for the epidermal growth factor receptor (EGFR), which is over-expressed by 25-80% of colorectal cancer tumours and associated with advanced disease. Cetuximab induces a broad range of cellular responses in tumours expressing EGFR, enhancing sensitivity to radiotherapy and chemotherapeutic agents. In a large, randomised, open-label, m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Preventive Medicine
سال: 2015
ISSN: 2008-7802
DOI: 10.4103/2008-7802.161068